Abstract
From July through September 1986, we carried out a clinical study on TE-031 (A-56268), a new macrolide antibiotic, by orally administering the drug to 14 patients (3 of the original 17 having dropped out) with purulent skin disease. The patients were divided into Group I, 8 cases of folliculitis, etc.; Group II, 2 cases of furuncle, etc.; Group III, one case of impetigo contagiosa; Group IV, 2 cases of phlegmon; and Group V, one case of infected atheroma. Evaluation of clinicalefficacy was: excellent 4, good 4, fair 3, and poor 3 cases, with an efficacy rate of 57.1%. We surmise that this low efficacy rate was partly bacause many patients in Group I had moderate or severe folliculitis or acne conglobata.
Four patients were given 200 mg of TE-031 orally, skin tissue specimens were collected about 4 hours later, and the concentration of TE-031 determined. The highest level detected was 6.35 μg/g, and in 3 of the 4 it was 5-6 times higher than in serum.
